ArticleFrontiers in plant science2019
Critical Analysis of the Commercial Potential of Plants for the Production of Recombinant Proteins.
Article in Frontiers in plant science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 130 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
130 citing papers in PubMed, 1 synthesis or guideline pooled it, 245 citations in OpenAlex.
- Bioengineered elastin- and silk-biomaterials for drug and gene delivery.Advanced drug delivery reviews · 2020Pooled it
- Quinoa and Peanut Extracts as Alternatives to Animal-Derived Extracellular Matrix Proteins in Cultured Meat Production.Journal of food science · 2026Article
- Review
- Recombinant basic fibroblast growth factor produced in Nicotiana benthamiana enhances cell viability and wound healing.Biotechnology letters · 2026Article
- Beyond Starch: Towards a Scalable Potato Platform for Molecular Farming.Plant biotechnology journal · 2026Review
- Evaluation of a high throughput multiparallel stirred bioreactor system using an apple cell line.Scientific reports · 2026Article
- Review
- Advances in plant metabolic engineering through synthetic biology.Frontiers in plant science · 2026Review
- Functional integration of LCIB, a component of the algal carbon-concentrating mechanism, enhances carbon assimilation, nitrogen-use efficiency, and biomass in tobacco.Frontiers in plant science · 2026Article
- Streamlined molecular farming of plant virus therapeutics for space flight and other low-resource environments.NPJ science of plants · 2026Article
- Protein nanoparticle-based vaccine candidate produced inFrontiers in plant science · 2026Article
- Plant-Based Ligand-Depletion Binding Assay for Assessing Pattern Recognition Receptor-Ligand Interactions.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Protein-Derived Signal Peptides Induced by Agrobacterium Infection Promote the Secretion of Recombinant Proteins in Nicotiana benthamiana.Plant biotechnology journal · 2026Article
- Structural Design and Immunogenicity of a Novel Self-Adjuvanting Mucosal Vaccine Candidate for SARS-CoV-2 Expressed in Plants.Plant biotechnology journal · 2026Article
- Developing downstream processes for the purification of recombinant proteins and small molecules from Nicotiana benthamiana biomass.Plant biotechnology journal · 2026Review
- CRISPR/Cas9-Mediated Knockouts of the ALG3 and GNTI in N. benthamiana and Their Application to Pharmaceutical Production.Plant biotechnology journal · 2025Article
- Somatic Embryogenesis: A Biotechnological Route in the Production of Recombinant Proteins.Biotech (Basel (Switzerland)) · 2025Review
- Catch & Release-rapid cost-effective protein purification from plants using a DIY GFP-Trap-protease approach.The Plant journal : for cell and molecular biology · 2025Article
- Production and purification of tag-free recombinant human acid sphingomyelinase in Nicotiana benthamiana.Plant cell reports · 2025Article
- Production Technologies for Recombinant Antibodies: Insights into Eukaryotic, Prokaryotic, and Transgenic Expression Systems.Biochemical genetics · 2025Review
70 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the last three decades, the expression of recombinant proteins in plants and plant cells has been promoted as an alternative cost-effective production platform. However, the market is still dominated by prokaryotic and mammalian expression systems, the former offering high production capacity at a low cost, and the latter favored for the production of complex biopharmaceutical products. Although plant systems are now gaining widespread acceptance as a platform for the larger-scale production of recombinant proteins, there is still resistance to commercial uptake. This partly reflects the relatively low yields achieved in plants, as well as inconsistent product quality and difficulties with larger-scale downstream processing. Furthermore, there are only a few cases in which plants have demonstrated economic advantages compared to established and approved commercial processes, so industry is reluctant to switch to plant-based production. Nevertheless, some plant-derived proteins for research or cosmetic/pharmaceutical applications have reached the market, showing that plants can excel as a competitive production platform in some niche areas. Here, we discuss the strengths of plant expression systems for specific applications, but mainly address the bottlenecks that must be overcome before plants can compete with conventional systems, enabling the future commercial utilization of plants for the production of valuable proteins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.